Skip to main content
. 2017 Nov 6;58(3):357–363. doi: 10.1002/jcph.1025

Table 5.

Adverse Events (Treated Set)

n (%) Child‐Pugh A (n = 8) Child‐Pugh B (n = 8) Healthy (n = 17)
Subjects with any AE 0 3 (37.5) 3 (17.6)
Headache 0 0 1 (5.9)
Diarrhea 0 1 (12.5) 0
Nausea 0 1 (12.5) 2 (11.8)
Vomiting 0 0 1 (5.9)
Pruritus 0 1 (12.5) 0
Skin irritation 0 1 (12.5) 0

Adverse events (AEs) were reported according to MedDRA version 17.1. AEs with onset between administration of trial medication and the end of the 28‐day posttreatment follow‐up period are shown.